Navigate Up
Launch the Developer Dashboard
CROI 2013 Network Presentations

CROI 2013 took place from March 3-6, 2013 in Atlanta, GA. This was the 20th Conference on Retroviruses and Opportunistic Infections.  To review the CROI program-at-a-glance, click here.

To view the network presentations for a particular network, click on the double arrow next to the network in the list of networks below.

 CROI 2013 Network Presentations

ACTG(EFV) pharmacokinetics (PK) are independently associated with virologic failure (VF) in diverse-resource limited settings
Andrade A., Baheti G., Smeaton L., Yang M., Kumarasamy N., Flanigan T., Hakim J., Klingman K., Campbell T., Fletcher C. Efavirenz
ACTGMicrobial translocation, inflammation and soluble and cellular immune activation biomarkers and HAART outcomes in resource-limited settings.
Balagopal A., Asmuth D., Smeaton L., Gupte N., Franco V., Hakim J., Pollard R., Campbell T., Thomas D., Gupta A.
ACTGGenotype, phenotype and susceptibility to new drugs among subtype C infected first-line failures.
Derache A., Wallis C., Miller M., Bartlett J., Aga E., Norton M., Klingman K., Hosseinipour M., Crump J., Supparatpinyo K., Kumarasamy N., Stevens W., Katzenstein D.
ACTGGenome-wide association study of phenotypic HIV-1 coreceptor usage in treatment naïve-patients from the ACTG A5095 trial.
Henrich T., McLaren P., Rao S., Lin N., Giguel F., Ribaudo H., Gulick R., de Bakker P., Kuritzkes D.
ACTGEffect of short course maternal antiretroviral regimens after single-dose nevirapine on HIV-1 transmission and drug resistance in infants: ACTG 5207
Hitti J., Halvas E., Zheng L., Taulo F., Kabanda J., Sprenger H., Klingman K., Chan E., McMahon D., Mellors J.
ACTGGenome-wide association study of atazanavir (ATV) pharmacokinetics (PK) and indirect hyperbilirubinemia (HBR).
Johnson D., Venuto C., Daar E., Morse G., Sax P., Fischl M., Collier A., McLaren P., Ritchie M., Haas D.
ACTGBaseline HIV drug resistance is independently associated with virologic failure in the multi-national PEARLS (ACTG A5175) study .
Kantor R., Smeaton L., Vardhanabhuti S., Tripathy S., Morgado M., Saravanan S., Wallis C., Hudelson S., Campbell T., Eshleman S.
ACTGLopinavir/ritonavir monotherapy after virologic failure of first line NNRTI-containing ART therapy in resource limited settings- wk 104 analysis of ACTG 5230.
Kumarasamy N., Aga E., Ribaudo H., Wallis C., Katzenstein D., Stevens W., Norton M., Klingman K., Bartlett J.
ACTGComparison of different FDA-cleared plasma HIV-1 RNA (VL) assay platforms for determination of virologic failure (VF) endpoints: an ACTG analysis.
Lalama C., Jennings C., Johnson V., Coombs R., McKinnon J., Bremer J., Cobb B., Cloherty G., Ribaudo H., Mellors J.
ACTGHIV transmission risk behavior in a cohort of HIV-infected treatment-naive men and women in the United States.
Landovitz R., Tran T., Cohn S., Ofotokun I., Lennox J., Currier J., Ribaudo H.
ACTGGenome-wide association study (GWAS) of peripheral neuropathy with stavudine/didanosine (d4T/ddI) in ACTG study 384.
Leger P., Johnson D., Robbins G., Shafer R., Clifford D., Li J., McLaren P., Haas D.
ACTGResidual viremia detected by single copy plasma HIV-RNA assay as an early predictor of virologic failure.
McKinnon J., Lalama C., Riddler S., Haubrich R., Hughes M., Vagratian D., Mellors J.
ACTGRenal insufficiency among women treated with tenofovir/emtricitabine/lopinavir/ritonavir (TDF/FTC/LPV/R) or TDF/FTC/nevirapine (NVP): analysis from the ACTG 5208 trial.
Mwafongo A., Nkanaunena K., Hosseinipour M., Lockman S., Hughes M., Currier J.
ACTGBaseline characteristics and acceptance of regimens recommended by an expert panel in ACTG A5241 OPTIONS, a randomized salvage HIV therapy trial.
Tashima K., Mollan K., Na L., Gandhi R., Klingman K., Fichtenbaum C., Andrade A., Johnson V., Eron J., Haubrich R.
ACTGOmitting NRTIs from ARV regimens is not inferior to adding NRTIs in treatment experienced HIV+ subjects failing a PI regimen: the ACTG OPTIONS study.
Tashima K., Smeaton L., Andrade A., Eron J., Fichtenbaum C., Gandhi R., Johnson V., Klingman K., Hollabaugh K., Haubrich R.
Late Breaker
ACTGRefining approaches to viral load monitoring using dried blood spots (DBS).
Wallis C., Aga E., Ribaudo H., Chevallier C., Stevens W., Kumarasamy N., Bartlett J., Katzenstein D.
ACTGDoes HIV-1 proviral DNA envelope sequence predict trofile coreceptor usage upon treatment interruption?
White E., Balamane M., Henry W., Margolis D., Valdez H., Tebas P., Skiest D., Katzenstein D.
ACTGEfficacy of different antiretroviral (ART) approaches after virologic failure (VF) on first-line ritonavir-boosted protease inhibitor (PI/r) regimens.
Zheng Y., Hughes M., Lockman S., Hosseinipour M., Campbell T., Salata R., Gulick R., Daar E., Benson C., Currier J.
ACTGChange in lean body mass and association with bone mineral density change in subjects randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: ACTG A5224s
Erlandson K., Kitch D., Tierney C., Sax P., Daar E., Tebas P., Melbourne K., Ha B., Jahed N., McComsey G.
ACTGLower baseline CD4 is associated with greater loss of bone mineral density (BMD) after antiretroviral therapy (ART) initiation.
Grant P., Kitch D., McComsey G., Dube M., Haubrich R., Huang J., Riddler S., Tebas P., Zolopa A., Brown T.
ACTGLong-term changes in renal parameters in ART-naive subjects randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: ACTG A5224s, a sub-study of A5202.
Gupta S., Kitch D., Tierney C., Sax P., Daar E., Szczech L., Tebas P., Ha B., Melbourne K., McComsey G.
ACTGProteinuria is associated with neurocognitive impairment in HIV infected subjects in the AIDS clinical trials group longitudinal cohort study.
Kalayjian R., Wu K., Evans S., Clifford D., Smurzynski M
ACTGThe prognostic capacity of CD8 T cell activation during effective antiretroviral therapy (ART) is attenuated by age.
Lok J., Hunt P., Deeks S., Collier A., Benson C., Witt M., Luque A., Bosch R.
ACTGSoluble markers of inflammation & coagulation, but not T-cell activation, predict non-AIDS-defining events during suppressive antiretroviral therapy.
Tenorio A., Zheng Y., Bosch R., Deeks S., Rodriguez B., Krishnan S., Hunt P., Wilson C., Lederman M., Landay A.
ACTGHIV-1 DNA decay patterns in blood during more than a decade of suppressive ART: results from ACTG NWCS 360.
Besson G., Lalama C., Bosch R., Gandhi R., Bedison A., Aga E., Riddler S., McMahon D., Hong F., Mellors J.
Late Breaker
ACTGPrevalence and patterns of residual viremia in HIV+ patients on long-term suppressive antiretroviral therapy (ART).
Riddler S., Aga E., Bosch R., Bedison A., Bastow B., Eron J., Gandhi R., Mellors J.
ACTGInitial therapy with raltegravir (RAL) increases clearance of 2-LTR circles but not total HIV DNA.
Strain M., Rought S., Lada S., Luong T., Woelk C., Andrade A., Kuritzkes D., Richman D.
ACTGThe effect of hepatitis C (HCV) virologic clearance on cardiovascular disease (CVD) biomarkers in HIV/HCV coinfection.
Chew K., Hua L., Bhattacharya D., Butt A., Chung R., Andersen J., Currier J.
ACTGVirologic and serologic outcomes in HIV/HBV co-infected, HBV Tx-naive on mono- and dual- HBV therapy in (ACTG longitudinal linked randomized trials- ALLRT).[
Kang M., Hollabaugh K., Pham V., Koletar S., Wu K., Smurzynski M., Aberg J. Virologic
ACTGAugmentation of interferon signaling by nitazoxanide in HIV/HCV coinfected subjects: an exploratory analysis from the ACTG5269 trial.
Lee Y., Osinusi A., Kang M., Umbleja T., Amorosa V., Kottilil S., Peters M.
1 - 30Next
Digg Delicious Facebook Newsvine Reddit StumbleUpon Twitter Email Link




© HIV/AIDS Network Coordination